Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 11/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.34 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358423 | 0.94 | BRS3 (0.40) | BRS3CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL14356227 | 0.89 | BRS3 (0.45) | BRS3CYP2C9MEN1KMT2AHPGD | |
| SCHEMBL5369392 | 0.87 | CYP2C9 (0.35) | BRS3CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL5366660 | 0.83 | BRD4 (0.40) | BRD4BRD2BRD3BRDTDYRK1A | |
| SCHEMBL13215288 | 0.82 | BRS3 (0.46) | BRS3CYP2C9MEN1KMT2AHPGD | |
| SCHEMBL5370915 | 0.81 | ALDH1A1 (0.35) | CYP2C9BRD4BRD2BRD3BRDT | |
| SCHEMBL5367609 | 0.78 | BRS3 (0.46) | BRS3CYP2C9MEN1KMT2AHPGD | |
| SCHEMBL5367233 | 0.77 | BRS3 (0.46) | BRS3CYP2C9ENPP2KMT2AHPGD | |
| SCHEMBL7009207 | 0.76 | BRS3 (0.51) | BRS3CYP2C9MEN1KMT2AHPGD | |
| SCHEMBL5361796 | 0.76 | BRS3 (0.48) | BRS3CYP2C9MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | BRS3 186/4885CYP2C9 59/4885BRD4 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.